Trial Profile
A Phase III Study to Evaluate the Efficacy and Safety of Fruquintinib in Combination With Paclitaxel Versus Paclitaxel Alone in Second Line Gastric Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Fruquintinib (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms FRUTIGA
- Sponsors Hutchison MediPharma; HUTCHMED
- 07 Feb 2024 Results published in the HUTCHMED Media Release.
- 07 Feb 2024 According to a HUTCHMED media release, data from this study was presented at the American Society of Clinical Oncology (ASCO) Plenary Series Session on February 6, 2024.
- 31 Jul 2023 According to a HUTCHMED media release, the company will submit the results from this trial to present at a scientific conference.